World Sepsis Day 2020: Calprotectin in sepsis

11. Sep 2020 | 6 min read

World Sepsis Day 2020: Calprotectin in sepsis


September is Sepsis awareness month, and the 9th World Sepsis Day, an initiative by the Global Sepsis Alliance (GSA), is held on 13th September 2020.


What is sepsis?

Sepsis is the leading cause of death among critically ill patients in intensive care units (ICU) with a continuously increasing incidence and a high mortality rate. Sepsis arises when the body’s response to an infection (bacterial, fungal or viral) starts to injure its own tissues and organs. This response might lead to septic shock with multi-organ failure, and death - especially if not recognised early and treated promptly [1]. You can find more information about sepsis at


 Sepsis diagnosis and monitoring, calprotectin



The following video from World Sepsis Day explains sepsis in 3 minutes - including the most common causes, symptoms, how it can be diagnosed and treated, and other useful information.


Calprotectin a promising sepsis biomarker

Calprotectin is a biomarker predominantly expressed in neutrophil granulocytes. It is released upon neutrophil activation in response to inflammation and/or infection. It is also one of the earliest biomarkers for detection of an inflammatory response, as well as for diagnosis of bacterial infections [2,3].

The levels of plasma calprotectin are significantly increased in patients with sepsis. A recent study has shown the ability of calprotectin to distinguish between patients with sepsis and trauma and to predict mortality in the ICU patients. Performance of calprotectin was superior to performance of procalcitonin (PCT) [4].

Calprotectin is also suggested as a useful biomarker for estimation of disease severity and prediction of severe events in patients with sepsis, including admission to a higher level of care and mortality [2,5].

World Sepsis Day. Calprotectin in diagnosis and monitoring


Need for early diagnosis

Rapid and correct diagnosis is essential in sepsis, as any delay in treatment leads to increased mortality. Calprotectin’s early response to inflammation and infections, combined with turbidimetric technology, will provide faster information and results on patient’s inflammatory response and infection status.

Gentian’s calprotectin Particle-Enhanced Turbidimetric Immunoassay (PETIA), GCAL®, has therefore potential applications for early detection and monitoring of sepsis and other severe bacterial infections, where it is critical to get fast access to results. GCAL® is rapidly performed in only 10 minutes and can be applied on a wide range of automated clinical chemistry analysers.


Want to know more about calprotectin?

Our Product Manager for GCAL® Calprotectin is eager to tell you more about calprotectin and ongoing studies. Send an email to: or fill out the form below.



  1. WSD 2020
  2. Fullerton J. et al. (2020). Meeting abstracts, Critical Care 2020, 24(Suppl 1):87
  3. Jonsson et al. (2017). Crit Care Resusc 19, 205-213
  4. Larsson et al. (2020). Scand J Clin Lab Invest. 2020 Feb - Apr;80(2):156-161
  5. Parke et al. (2020). Meeting abstracts, Critical Care 2020, 24(Suppl 1):87


You may also read

Gentian at AACC 2020

Nov 12, 2020

Gentian at AACC 2020

Meet us at #2020AACC Virtual Exhibit Hall  Gentian looks forward to meeting you at the AACC 2020, even it..

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

Oct 14, 2020

Gentian Newsletter Q3-2020 #DiagnosticEfficiency

We are looking forward to sharing news and exciting things that happened in the last few months. We have for..

Webinar: Frequently asked questions about cystatin C

Oct 06, 2020

Webinar: Frequently asked questions about cystatin C

#FAQ: Cystatin C In the third webinar of the cystatin C webinar series, Shanyil Wickramasinghe, Gentian’s US..